Clinical study on the usefullness of edoxaban tosilate hydrate to portal vein thrombosis complicated with chronic liver disease
- Conditions
- Portal vein thrombosis
- Registration Number
- JPRN-UMIN000030108
- Lead Sponsor
- Kanazawa University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Not provided
1. Child-Pugh classification C. 2. Endoscopic examination confirms the presence of lesions at risk of gastrointestinal bleeding (esophageal gastric varices, gastric / duodenal ulcers, gastric antral vascular dilation, etc.), and does not perform prophylactic treatment. 3. Have active malignancy. 4. Patients taking anticoagulant or / and antiplatelet drugs. 5. Patients with a history of clear bleeding symptoms such as cerebral haemorrhage. 6. Patients who weigh less than 40 kg at registration. 7. A woman who is pregnant or has a possibility of pregnancy, within 28 days after childbirth or breast-feeding. A man who wishes to become a partner's pregnant. 8. Mental illness or psychiatric symptoms are merged and it is judged that participation in the examination is difficult. 9. It has severe hypersensitivity to the ingredients of Edoxaban. 10. Because of drug allergy, neither CT nor MRI using a contrast agent can be performed. 11. Others, the doctor in charge determines that participation in this examination is inappropriate.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduction rate of portal vein thrombus 14 days after edoxaban administration
- Secondary Outcome Measures
Name Time Method Safety of edoxaban administration against portal vein thrombosis